Une étude comparant le Siplizumab au globuline anti-thymocyte de lapin pour aider l'organisme à accepter une greffe de rein (MODERNIZE1)
Étude de phase 2b, randomisée, multicentrique, en double aveugle, de recherche de dose, contrôlée active, du siplizumab (TCD601) comparé à la globuline anti-thymocytes de lapin chez des receveurs de greffe rénale nécessitant un traitement d’induction et recevant un traitement immunosuppresseur standard avec du tacrolimus, de l’acide mycophénolique et des corticostéroïdes
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brésil, 30150-320
- Recrutement
- Santa Casa Demisericordia de Belo Horizonte
-
Contact:
- Pedro Macedo de Souza
- Numéro de téléphone: +55 (31) 3238-8975
- E-mail: pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90035-903
- Recrutement
- Hospital de Clinicas de Porto Alegre
-
Contact:
- Research Coordinator
- Numéro de téléphone: +55 51 3359-6253
- E-mail: l-genetica@hcpa.edu.br
-
Porto Alegre, Rio Grande do Sul, Brésil, 90020-090
- Recrutement
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
Contact:
- Research Coordinator
- Numéro de téléphone: +55 51 3214-8640
- E-mail: pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto, São Paulo, Brésil, 15090-000
- Recrutement
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
Contact:
- Research Coordinator
- Numéro de téléphone: +55 (17) 3201-5054
- E-mail: osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo, São Paulo, Brésil, 04038-002
- Recrutement
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
Contact:
- Research Coordinator
- Numéro de téléphone: +55 (11) 5087-8110
- E-mail: hospital@hrim.com.br
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Hospital Universitari Vall D'Hebron
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34 932746000
- E-mail: assajos.nefrologia@vhir.org
-
Córdoba, Espagne, 14004
- Recrutement
- Hospital Universitario Reina Sofía
-
Contact:
- Álvaro Torres, MD
- Numéro de téléphone: +34 957010440
- E-mail: nefro.hrs.sspa@juntadeandalucia.es
-
Málaga, Espagne, 29010
- Recrutement
- Hospital Universitario Regional de Malaga
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34 951291174
- E-mail: estudios.clinicos@ibima.eu
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- Keck Hospital of the University of Southern California
-
Contact:
- Melissa Ramos
- Numéro de téléphone: 323-442-7983
- E-mail: Melissa.Ramos@med.usc.edu
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
Contact:
- Suphamai Bunnapradist, MD
- Numéro de téléphone: 310-794-8516
- E-mail: bunnapradist@mednet.ucla.edu
-
Sacramento, California, États-Unis, 95817
- Recrutement
- UC Davis Medical Center
-
Contact:
- Timothy Huynh, Clinical Research Coordinator
- Numéro de téléphone: 916-703-4471
- E-mail: ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa, Florida, États-Unis, 33606
- Recrutement
- Tampa General Hospital
-
Contact:
- Jennifer Schmidt, BSN, RN
- Numéro de téléphone: 813-844-7041
- E-mail: jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University Hospital
-
Contact:
- Emily Temponi, Study Coordinator
- Numéro de téléphone: 404-712-1114
- E-mail: emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Recrutement
- University of Kansas Hospital
-
Contact:
- Adam Schooley, MA, CCRP
- Numéro de téléphone: 913-588-1699
- E-mail: aschooley@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- Recrutement
- University of Kentucky Healthcare
-
Contact:
- Malay Shah, MD
- Numéro de téléphone: 859-338-1615
- E-mail: malay.shah@uky.edu
-
-
Louisiana
-
Metairie, Louisiana, États-Unis, 70006
- Recrutement
- Tulane Medical Center
-
Contact:
- Nicole Jackson
- Numéro de téléphone: 504-988-5344
- E-mail: njackson3@tulane.edu
-
-
Massachusetts
-
Worcester, Massachusetts, États-Unis, 01655
- Recrutement
- UMass Chan Medical Center
-
Contact:
- Anil Chandraker, MD
- Numéro de téléphone: 508-334-7087
- E-mail: anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan - Michigan Medicine
-
Contact:
- Nerissa Reister, Clinical Research Coordinator
- Numéro de téléphone: 734-763-5718
- E-mail: naflow@med.umich.edu
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Health
-
Contact:
- Matthew Callaghan
- Numéro de téléphone: 313-916-4596
- E-mail: mcallag2@hfhs.org
-
-
New Jersey
-
Livingston, New Jersey, États-Unis, 07039
- Recrutement
- Cooperman Barnabus Medical Center
-
Contact:
- Jayrol Mock, APN
- Numéro de téléphone: 973-322-2339
- E-mail: Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York, New York, États-Unis, 10032
- Recrutement
- New York Presbyterian - Columbia University Irving Medical School
-
Chercheur principal:
- Lloyd Ratner, MD
-
Contact:
- Angela Sanchez, CRC
- Numéro de téléphone: 212-305-3839
- E-mail: as5546@cumc.columbia.edu
-
Contact:
- Theresa Lukose, Research Director
- Numéro de téléphone: 212-305-3839
- E-mail: tt2103@cumc.columbia.edu
-
New York, New York, États-Unis, 10065
- Recrutement
- New York Presbyterian - Weill Cornell Medical Center
-
Contact:
- Jennifer Lee
- Numéro de téléphone: 212-746-0192
- E-mail: jel9109@nyp.org
-
Contact:
- Meredith Aull
- Numéro de téléphone: 212-746-5330
- E-mail: mea9008@med.cornell.edu
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Medical Center
-
Contact:
- Lynnette Moats
- Numéro de téléphone: 919-949-6574
- E-mail: lynnette.moats@duke.edu
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- Recrutement
- University of Texas Southwestern Medical Center
-
Contact:
- David Wojciechowski, DO
- Numéro de téléphone: 214-645-7846
- E-mail: David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church, Virginia, États-Unis, 22042
- Recrutement
- Inova Fairfax Hospital
-
Contact:
- Alma Khan, MSN, CCRC
- Numéro de téléphone: 703-776-5912
- E-mail: Alma.Khan2@inova.org
-
Richmond, Virginia, États-Unis, 23298
- Recrutement
- Virginia Commonwealth University Health
-
Contact:
- Meron Zeleke
- Numéro de téléphone: 804-628-4969
- E-mail: Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- Recrutement
- University of Washington Medical Center
-
Contact:
- Belinda Pan, Research Coordinator
- Numéro de téléphone: 206-598-1562
- E-mail: bcpan@uw.edu
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Siplizumab à faible dose
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Autres noms:
|
|
Expérimental: Siplizumab à haute dose
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Autres noms:
|
|
Comparateur actif: Globuline anti-thymocyte de lapin
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Délai: 12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Délai: 12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Délai: 12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Délai: 12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Comportement
- Comportement social
- Rejet, Psychologie
- Acides aminés, peptides et protéines
- Protéines
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Produits biologiques
- Mélanges complexes
- Sérums immunitaires
- Sérum antilymphocytaire
- thymoglobuline
- siplizumab
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- TCD601B205
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .